Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCNGet Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 3.1 %

Shares of LPCN stock opened at $4.05 on Wednesday. The stock has a market cap of $21.53 million, a P/E ratio of -1.29 and a beta of 1.05. The stock has a 50 day simple moving average of $3.17 and a 200 day simple moving average of $3.34. Lipocine has a 1 year low of $2.31 and a 1 year high of $9.52.

Lipocine (NASDAQ:LPCNGet Free Report) last announced its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.70). The business had revenue of ($3.12) million for the quarter. Analysts forecast that Lipocine will post -2.99 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in Lipocine by 0.4% during the first quarter. BlackRock Inc. now owns 1,467,420 shares of the specialty pharmaceutical company’s stock valued at $467,000 after purchasing an additional 6,348 shares in the last quarter. State Street Corp increased its holdings in shares of Lipocine by 7.5% during the first quarter. State Street Corp now owns 327,405 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 22,788 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Lipocine during the first quarter worth $54,000. Renaissance Technologies LLC increased its holdings in shares of Lipocine by 474.5% during the second quarter. Renaissance Technologies LLC now owns 81,006 shares of the specialty pharmaceutical company’s stock worth $65,000 after buying an additional 66,906 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Lipocine by 524.6% during the first quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock worth $121,000 after buying an additional 74,428 shares in the last quarter. 8.99% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

(Get Free Report)

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Featured Articles

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.